Weave Bio leverages generative AI with AutoIND to transform the IND application process, expediting regulatory filings, cutting costs, and accelerating the delivery of life-saving therapies to patients.

Relation deploys active-graph machine learning (ML) combined with single-cell analysis to advance therapeutic candidates for diseases with no or few good medicines.

Resilience is changing the way complex medicines are made and distributed by leveraging technology innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.

Paradigm is an intelligent, deep-tech clinical research platform that designs and runs more impactful clinical trials.

Terrain Bioscience is making better RNA faster, using AI/ML-guided optimization and improved manufacturing processes to accelerate therapeutic innovation for partners.

Doppler Bio is building a reprogrammable ADAR sensor platform to detect disease-associated RNAs and produce engineered proteins to manipulate cell states without permanent genome editing.

Deep Genomics uses artificial intelligence and machine learning to rapidly accelerate drug discovery and development for rare genetic and chronic diseases.

HiberCell is developing first-in-class drugs that target dormant disseminated tumor cells to help prevent the recurrence of cancer.

Unlocking cellular profiling and target discovery with epitope resolution.

Transition Bio is unlocking the potential of microfluidics and machine learning (ML) to discover modulators of biomolecular condensates in human disease.

Triveni Bio uses state of the art antibody discovery and optimization strategies, to selectively inhibit extracellular enzymes that, when overactive, can cause broad inflammatory response.

AppliedVR has pioneered evidence-based, immersive VRx—a new category of prescription digital therapeutics.